These data show that the protective efficacy in G-exo-stimulated DC vaccination correlated with the generation of tumor antigen-specific multifunctional CD4+ and CD8+ T cells and suggest that the use of the DC vaccine as an exosome delivery system is expected to be a potent strategy to supplement tumor exosome-mediated immunosuppression. The gene discussed is CD8A; the disease is neoplasm.